Pancreatic Cancer Research

ResearcherThe University of OsakaActive in the last 2 years

Teppei Yoshioka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3608-0554; OpenAlex author ID A5004665162. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 8

  1. Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk. First author DOI 10.1007/s00330-026-12740-z↗
  2. The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary mucinous neoplasia. Co-author DOI 10.1016/j.pan.2023.11.005↗
  3. The serum tenascin C level is a marker of metabolic disorder-related inflammation affecting pancreatic cancer prognosis. Co-author DOI 10.1038/s41598-024-62498-x↗
  4. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity. Co-author DOI 10.1186/s13046-023-02831-w↗
  5. Pentraxin 3 is an adipose tissue-related serum marker for pancreatic cancer cachexia predicting subsequent muscle mass and visceral fat loss. Co-author DOI 10.1111/cas.15569↗
  6. Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions. Co-author DOI 10.1097/mpa.0000000000001521↗
  7. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels. Co-author DOI 10.1371/journal.pone.0235573↗
  8. Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. Co-author DOI 10.1016/j.bbrc.2019.07.020↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tetsuo Takehara · 7 shared papers, 2019–2024 · strength 0.87
  2. Katsuhiko Sato · 6 shared papers, 2020–2024 · strength 0.78
  3. Hidetoshi Eguchi · 2 shared papers, 2023–2026 · strength 0.39
  4. Kenji Ikezawa · 3 shared papers, 2019–2024 · strength 0.35
  5. Junya Okabe · 2 shared papers, 2023–2024 · strength 0.30
  6. Noriyuki Tomiyama · 1 shared paper, 2026 · strength 0.25
  7. Yasunari Fukuda · 1 shared paper, 2026 · strength 0.25
  8. Hideyuki Fukui · 1 shared paper, 2026 · strength 0.25
  9. Daisaku Yamada · 1 shared paper, 2026 · strength 0.25
  10. Tadashi Kegasawa · 2 shared papers, 2019–2024 · strength 0.25
  11. Takuo Yamai · 2 shared papers, 2020 · strength 0.20
  12. Kengo Matsumoto · 1 shared paper, 2024 · strength 0.16
  13. Motohiro Hirao · 1 shared paper, 2024 · strength 0.16
  14. Masaya Higashiguchi · 1 shared paper, 2023 · strength 0.14
  15. Kazuma Daiku · 1 shared paper, 2023 · strength 0.14
  16. Makiko Urabe · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.